Follow-up program for childhood blood cancer survivors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study creates a structured follow-up program for children and teens who have finished treatment for blood cancers like leukemia or lymphoma. It aims to help survivors stay healthy and catch any late effects of treatment early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with a blood cancer like leukemia or lymphoma as a child.
- You finished your main treatment at least 12 months ago.
- You are between 1 and 21 years old.
- You can come to follow-up visits and share medical information.
- You or your parents understand and agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at the medical records of children and young adults diagnosed with cancer in the last 15 years. It helps researchers understand more about cancer in young people.
This study follows children and teens with newly diagnosed certain leukemia (ALL) and certain favorable brain tumors to learn best care and outcomes. It may help your team compare standard treatments and monitor health over time.
This study is collecting long-term follow-up information from people diagnosed with certain blood and bone marrow conditions. It may help doctors understand what happens over time and improve future care, but you’re mainly contributing data rather than receiving a new treatment.
This study looks at whether a simple blood test can help track how well treatment is working in children with leukemia. It may help doctors understand the disease better and guide future care.
This study enrolls adults with certain blood cancers to better understand diagnosis, treatment choices, and outcomes. You may also be asked to provide or have tissue/blood samples saved so researchers can study what’s going on in the disease.
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.